Antithymocyte Immunoglobulins Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 25mg, 100 mg, 500 mg
Reference Brands: Thymoglobulin (USA/EU/LATAM), Fresenius ATG (EU)
Category:
Transplant
This injection is a purified and sterile form of gamma globulin. It is isolated from the hyperimmune plasma of horses immunized with human white blood cell components. It is used after kidney transplantation along with other therapies to treat as well as delay organ rejection.
ANTITHYMOCYTE IMMUNOGLOBULINS INJECTION is available in Injection
and strengths such as 25mg, 100 mg, 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, ANTITHYMOCYTE IMMUNOGLOBULINS INJECTION is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
ANTITHYMOCYTE IMMUNOGLOBULINS INJECTION can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
After solid organ transplantation, the body generates an aggressive immune response because it recognizes the transplanted organ's antigens as a foreign antigen. Thus, treatment with immunosuppressive agents is necessary after an organ transplant to prevent organ rejection.
Antithymocyte Globulin (ATG) is a purified antibody preparation derived from rabbits or horses that have been hyperimmunized with human thymocytes. It is a potent immunosuppressive agent used primarily to prevent and treat acute cellular rejection following solid organ transplantation, including kidney, heart, and liver transplants. ATG is also employed in the management of acute aplastic anemia and other severe immune-mediated hematologic disorders. By targeting T-lymphocytes, ATG reduces the immune response, helping to prevent graft-versus-host disease and improve transplant outcomes.
Although ATG is highly effective, it can cause transient elevations in serum enzymes shortly after infusion, and it carries a risk of reactivating hepatitis B in susceptible patients. Common adverse effects include fever, chills, hypotension, and infusion-related reactions, which typically require careful monitoring during administration. Its mechanism, dosing, and safety profile necessitate skilled oversight by healthcare professionals. Overall, ATG remains an essential therapy in transplantation and certain hematologic conditions due to its ability to modulate the immune system effectively while reducing the risk of organ rejection and immune-mediated complications.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing